Auricular vagus nerve stimulation for mitigation of inflammation and vasospasm in subarachnoid hemorrhage: a single-institution randomized controlled trial
Authors:
Open Access
- 1 June 2025
- journal article
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 142 (6) , 1720-1731
Abstract
OBJECTIVE: Inflammation contributes to morbidity following subarachnoid hemorrhage (SAH). The authors of this study evaluate how applying noninvasive transauricular vagus nerve stimulation (taVNS) can target this deleterious inflammatory response following SAH and reduce the rate of radiographic vasospasm. METHODS: In this prospective, triple-blinded, randomized controlled trial, 27 patients were randomized to taVNS or sham stimulation. Serial blood and CSF samples were collected every 3 days to quantify inflammatory markers. Radiographic cerebral vasospasm severity and functional outcomes (modified Rankin Scale scores) were analyzed. RESULTS: No adverse events occurred. Radiographic vasospasm was significantly reduced (p = 0.018), with serial vessel caliber measurements demonstrating a more rapid return to normal than in the sham-treated group (p < 0.001). In the taVNS group, tumor necrosis factor–α was significantly reduced in both plasma (days 7 and 10) and CSF (day 13); interleukin-6 was also significantly reduced in plasma (day 4) and CSF (day 13) (p < 0.05). Patients receiving taVNS had higher rates of favorable outcomes at discharge (38.4% vs 21.4%) and first follow-up (76.9% vs 57.1%). Patients treated with taVNS had significant improvement in modified Rankin Scale scores from admission to first follow-up (p = 0.014), unlike patients in the sham-treated group (p = 0.18). The taVNS group had a significantly lower rate of discharge to a skilled nursing facility or hospice (p = 0.04). CONCLUSIONS: taVNS is a noninvasive method of neuro- and systemic immunomodulation. This trial supports the finding that taVNS following SAH can mitigate the inflammatory response, reduce radiographic vasospasm, and potentially improve functional and neurological outcomes.Keywords
This publication has 39 references indexed in Scilit:
- Diagnosis and management of subarachnoid haemorrhageNature Communications, 2024
- Central sympathetic nerve activation in subarachnoid hemorrhageJournal of Neurochemistry, 2021
- Interleukin 6 in cerebrospinal fluid is a biomarker for delayed cerebral ischemia (DCI) related infarctions after aneurysmal subarachnoid hemorrhageScientific Reports, 2021
- TNF-R1 Correlates with Cerebral Perfusion and Acute Ischemia Following Subarachnoid HemorrhageNeurocritical Care, 2020
- Spreading Depolarizations and Subarachnoid HemorrhageNeurotherapeutics, 2020
- Interleukin-6 Levels in Cerebrospinal Fluid and Plasma in Patients with Severe Spontaneous Subarachnoid HemorrhageWorld Neurosurgery, 2019
- A Propensity Score Analysis of the Impact of Dexamethasone Use on Delayed Cerebral Ischemia and Poor Functional Outcomes After Subarachnoid HemorrhageWorld Neurosurgery, 2018
- Early Dynamics of Interleukin-6 in Cerebrospinal Fluid after Aneurysmal Subarachnoid HemorrhageJournal of Neurological Surgery Part A: Central European Neurosurgery, 2017
- Balancing the autonomic nervous system to reduce inflammation in rheumatoid arthritisJournal of Internal Medicine, 2017
- Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritisProceedings of the National Academy of Sciences, 2016